And the potential FTO inhibitor entacapone elicits glucose-lowering function in vivo.206 Moreover, unregulated activating transcription factor 4 (ATF4) was found in FTO-overexpressed transgenic mice, which could augment glucose production by modulating G6P.207,208 Moreover, m6A modification exerts regulatory roles in insulin resistance (IR). The gene discussed is FTO; the disease is Insulin resistance.